Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Antiangiogenic VEGF isoform in inflammatory myopathies.
[inclusion body myositis]
To
investigate
expression
of
vascular
endothelial
growth
factor
(
VEGF
)
antiangiogenic
isoform
A-
165
b
on
human
muscle
in
idiopathic
inflammatory
myopathies
(
IIM
)
and
to
compare
distribution
of
angiogenic
/
antiangiogenic
VEGFs
,
as
isoforms
shifts
are
described
in
other
autoimmune
disorders
.
We
analyzed
VEGF-A
165
b
and
VEGF-A
by
western
blot
and
immunohistochemistry
on
skeletal
muscle
biopsies
from
21
patients
affected
with
IIM
(
polymyositis
,
dermatomyositis
,
and
inclusion
body
myositis
)
and
6
control
muscle
samples
.
TGF-
β
,
a
prominent
VEGF
inductor
,
was
analogously
evaluated
.
Intergroup
differences
of
western
blot
bands
density
were
statistically
examined
.
Endomysial
vascularization
,
inflammatory
score
,
and
muscle
regeneration
,
as
pathological
parameters
of
IIM
,
were
quantitatively
determined
and
their
levels
were
confronted
with
VEGF
expression
.
V
EGF-A
165
b
was
significantly
upregulated
in
IIM
,
as
well
as
TGF-
β
.
VEGF-A
was
diffusely
expressed
on
unaffected
myofibers
,
whereas
regenerating
/
atrophic
myofibres
strongly
reacted
for
both
VEGF-A
isoforms
.
Most
inflammatory
cells
and
endomysial
vessels
expressed
both
isoforms
.
VEGF-A
165
b
levels
were
in
positive
correlation
to
inflammatory
score
,
endomysial
vascularization
,
and
TGF-
β
.
Our
findings
indicate
skeletal
muscle
expression
of
antiangiogenic
VEGF-A
165
b
and
preferential
upregulation
in
IIM
,
suggesting
that
modulation
of
VEGF-A
isoforms
may
occur
in
myositides
.
Diseases
Validation
Diseases presenting
"muscle biopsies"
symptom
cadasil
inclusion body myositis
pyruvate dehydrogenase deficiency
zellweger syndrome
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom